Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
Type:
Grant
Filed:
October 5, 2017
Date of Patent:
June 27, 2023
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.
Type:
Grant
Filed:
September 24, 2019
Date of Patent:
June 6, 2023
Assignees:
Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
Inventors:
Jeffrey A. Medin, Lawrence G. Lum, Robyn A. A. Oldham, Archana Thakur
Abstract: The purpose of the present invention is to provide an antibody that can be expected to have a therapeutic effect in autoimmune diseases and anticancer treatment by inhibiting S1P transport by SPNS2 to thereby inhibit lymphocyte migration. The present invention is an SPNS2 neutralizing antibody or a fragment thereof, or a derivative thereof, that specifically binds to vertebrate SPNS2 and has lymphocyte migration inhibitory activity through SW transport inhibition.
Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
Type:
Grant
Filed:
August 11, 2022
Date of Patent:
May 23, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Abstract: The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases.
Type:
Grant
Filed:
February 4, 2021
Date of Patent:
May 9, 2023
Assignee:
Regeneran Pharmaceuticals, Inc.
Inventors:
Panayiotis Stevis, Andrew J. Murphy, Jesper Gromada, Yonaton Ray, Jee H. Kim, Ivan B. Lobov
Abstract: The invention relates to monoclonal antibodies which specifically bind to the TRBV9 family of human T-cell receptors. The invention also relates to a nucleic acid which codes for said antibody or for an antigen-binding fragment thereof, to an expression vector, to a method for producing the antibody, and to the use of said antibody for treating diseases or disorders associated with the family of human T-cell receptors. The invention is directed towards producing antibodies that can be used for eliminating T-cells carrying T-cell receptors of the TRBV9 family, in particular for treating ankylosing spondylitis, coeliac disease, and blood cancers, in the pathogenesis of which T-cell receptors of the TRBV9 family are involved.
Type:
Grant
Filed:
December 25, 2018
Date of Patent:
March 7, 2023
Inventors:
Olga Vladimirovna Britanova, Mark Aleksandrovic Izraelson, Sergey Anatolievich Lukyanov
Abstract: The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.
Type:
Grant
Filed:
September 24, 2019
Date of Patent:
February 21, 2023
Assignees:
Medical College of Wisconsin, Inc., University of Virginia Patent Foundation
Inventors:
Jeffrey A. Medin, Mary L. Faber, Everett R. Tate, Robyn A. A. Oldham
Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
February 14, 2023
Assignee:
The University of Vermont and State Agriculture College
Abstract: The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone.
Type:
Grant
Filed:
April 25, 2019
Date of Patent:
February 14, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Nicholas J. Papadopoulos, Andrew J. Murphy, Aris N. Economides, Katherine Diana Cygnar
Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.
Type:
Grant
Filed:
August 18, 2020
Date of Patent:
January 31, 2023
Assignee:
NGM Biopharmaceuticals, Inc.
Inventors:
Chun Chu, Xunshan Ding, Zhonghao Liu, Yan Wang, Yiyuan Yin, Wenwu Zhai
Abstract: In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.
Type:
Grant
Filed:
February 4, 2020
Date of Patent:
January 3, 2023
Assignee:
Board of Regents of The University Of Nebraska
Inventors:
Geoffrey M. Thiele, Daniel R. Anderson, Michael J. Duryee
Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
Abstract: Novel antibodies, such as single domain antibodies (sdAbs), or antigen-binding fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are also described.
Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
Type:
Grant
Filed:
November 28, 2017
Date of Patent:
November 15, 2022
Assignee:
Sung Kyun Biotech Co., Ltd.
Inventors:
Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
Abstract: Provided herein are formulations of PCSK9-binding polypeptides, such as those comprising evolocumab, that comprise N-acetyl arginine and have reduced viscosities when compared to formulations lacking N-acetyl arginine. Provided herein are also methods of formulating such compositions that are advantageous in that they conserve certain components. Such formulations comprising PCSK9-binding polypeptides can be administered to patients to treat and/or prevent PCSK9-related diseases, conditions, and disorders.
Type:
Grant
Filed:
February 22, 2018
Date of Patent:
October 11, 2022
Assignee:
AMGEN INC.
Inventors:
Christopher James Sloey, Sekhar Kanapuram, Huanchun Cui, Chio Mui Chan, Elaheh Binabaji
Abstract: Provided herein are agents that hind to binding domain I of LRP1 and mimic the activity of prosaposin in stimulating Tsp-1. Further provided herein are agents that inhibit the function (e.g., the ability to repress Tsp-1) of Protease, Serine 2 (PRSS2) by inhibiting the binding of PRSS2 to LRP1. Methods of using these agents in treating cancer are also provided.
Abstract: The present invention relates to modified bacterial polypeptides having immunomodulatory and immunostimulatory activity. Most specifically, the present invention relates to modified bacterial polypeptides having an amino acid sequence selected from SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5. The modified polypeptides are the adjuvant components of a pharmaceutical composition for eliciting an immune response against an specific antigen present in the pharmaceutical composition. In a preferred embodiment, the invention provides a pharmaceutical composition for a vaccine which comprises an adjuvant component which is any one of the modified polypeptides, one or more antigens, together with a pharmaceutically acceptable excipient.
Type:
Grant
Filed:
February 8, 2019
Date of Patent:
October 4, 2022
Assignees:
CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET, UNIVERSIDAD NACIONAL DE GENERAL SAN MARTIN
Inventors:
Mirta L. Coria, Karina A. Pasquevich, Juliana Cassataro